Gross Profit Comparison: Dr. Reddy's Laboratories Limited and Amphastar Pharmaceuticals, Inc. Trends

Pharma Giants' Profit Trends: A Decade of Growth

__timestampAmphastar Pharmaceuticals, Inc.Dr. Reddy's Laboratories Limited
Wednesday, January 1, 20145125600075801000000
Thursday, January 1, 20157734700085403000000
Friday, January 1, 201610418900092281000000
Sunday, January 1, 20179079500078356000000
Monday, January 1, 201810698500076304000000
Tuesday, January 1, 201913192300083430000000
Wednesday, January 1, 202014334000094009000000
Friday, January 1, 2021199739000103077000000
Saturday, January 1, 2022248860000113840000000
Sunday, January 1, 2023351121000202972000000
Monday, January 1, 2024163607000000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Pharmaceutical Giants: Gross Profit Trends

In the ever-evolving pharmaceutical industry, financial performance is a key indicator of a company's success. This analysis compares the gross profit trends of Dr. Reddy's Laboratories Limited and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Dr. Reddy's Laboratories consistently outperformed Amphastar, with gross profits peaking at approximately $203 billion in 2023, a remarkable 167% increase from 2014. In contrast, Amphastar's gross profit grew by an impressive 585%, reaching around $351 million in 2023. This stark difference highlights Dr. Reddy's dominant market position, while Amphastar's rapid growth trajectory showcases its potential. Notably, data for 2024 is incomplete, leaving room for speculation on future trends. As these companies continue to innovate and expand, their financial journeys offer valuable insights into the competitive landscape of the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025